MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Saturday, October 28, 2017

Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a


OCT 28, 2017
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a 

Currently there are no specifically approved disease modifying therapies for children and adolescents with MS, a population at high risk of long-term disability

MS is a highly debilitating disease which touches every aspect of young patients' daily lives, from school performance to family relations and friendships

The digital press release with multimedia content can be accessed here: 

Basel, October 28, 2017 - Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya® (fingolimod) vs. interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS). Treatment with oral Gilenya resulted in an 82% reduction in the rate of relapses (annualized relapse rate) over a period of up to two years, compared to interferon beta-1a intramuscular injections (p <0.001)[1]. PARADIGMS is the first ever controlled, randomized trial specifically designed for pediatric MS. The results have been presented at the 7th Joint European and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) meeting on October 28, 2017 in Paris, France.
"Pediatric MS patients experience more frequent relapses and are more likely to accumulate physical disability at an earlier age than patients diagnosed as adults," said Dr. Tanuja Chitnis, Principle Investigator for PARADIGMS and Director of the Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, Boston, US, and Scientist, Ann Romney Center, Brigham and Women's Hospital, Boston, US. "Yet, current therapies are limited to drugs that have not been tested in a controlled manner in this age group. PARADIGMS was uniquely designed for this patient population. Its results signify an important step towards a potential new treatment that could improve the lives of these young patients." 
Additional data from the study demonstrated:
  • A significant reduction in the number of new / newly enlarging T2 and Gd-T1 lesions in the brain of Gilenya treated patients compared to those treated with interferon beta-1a, as measured by magnetic resonance imaging (MRI)[1]. The number and volume of lesions are associated with increased relapses and disability progression[2].
  • Individuals treated with Gilenya had significantly less brain shrinkage (measured by MRI as brain volume loss), compared to those treated with interferon beta-1a[1]. Brain shrinkage in adults is associated with the loss of physical and cognitive function­[3].
  • The safety profile of Gilenya was overall consistent with that seen in previous clinical trials, with more adverse events reported in the interferon group[1].
  • In an additional analysis, Gilenya significantly delayed disability progression, defined as Confirmed Disability Progression (CDP), compared to interferon beta-1a[1].
"There is already substantial evidence that Gilenya is an effective treatment that improves long-term outcomes for adults with relapsing MS. We are delighted that PARADIGMS has shown such meaningful benefits for children and adolescents with MS," said Vas Narasimhan, Global Head of Drug Development and Chief Medical Officer, Novartis. "This pioneering study demonstrates our continued commitment to providing new treatment options to MS patients with the highest need. We look forward to working with health authorities and preparing for submission."
Gilenya is not currently approved for the treatment of pediatric MS. Novartis is working on submission with health authorities worldwide.
About the Phase III PARADIGMS study
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
...............................................................................

Friday, October 27, 2017

New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis


·       Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity (PIRA) in people with relapsing multiple sclerosis (RMS)

·       Data demonstrates first method to automatically detect and characterize Slowly Evolving Lesions (SELs) as a potential measure of underlying disease activity in the brain using MRI

·       New results from FLOODLIGHT study suggest smartphone-based disease progression monitoring can augment in-clinic tests, such as hand/arm function and walking behavior

South San Francisco, CA -- October 26, 2017 --
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data are being presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting in Paris, France. The data presented showcase clinical advances around underlying disease activity and disability progression in relapsing and progressive forms of multiple sclerosis (MS), through the exploration of newly emerging endpoints and precision monitoring.
OCREVUS significantly reduced the proportion of people with RMS who experienced Progression Independent of Relapse Activity (PIRA) in a post-hoc analysis compared to Rebif® (interferon-beta 1a). This effect was particularly seen in those who were potentially at higher risk of progressive disease course based on their baseline Expanded Disability Status Scale (EDSS). Specifically, in this analysis, OCREVUS treatment reduced the risk of PIRA by 25 percent and 23 percent confirmed at 12 and 24 weeks, respectively (p=0.008 and p=0.039, respectively).
PIRA is a newly emerging MS endpoint intended to measure an increase in disability, which is related to underlying disease activity in RMS. These data were generated through a post-hoc analysis of more than 1,600 people randomly assigned to treatment in OPERA I and OPERA II, and assessed for PIRA, as measured by cCDP. cCDP is a measure of the risk of a person’s physical disability getting worse and is based on three measures of physical disability – confirmed disability progression, walking speed and upper extremity function.
“These new analyses of data from the large controlled studies with OCREVUS help advance our understanding of how, in relapsing MS, the disease may progress independent of relapses. These insights have implications for daily decisions made together with patients,” said Ludwig Kappos, M.D., chair of the Department of Neurology, University Hospital, Basel, Switzerland. “Even without experiencing relapses, people with RMS may still have underlying disease activity, which can cause irreversible decline in their mobility and day-to-day quality of life. Recognizing and understanding this process supports early indication of more efficacious treatment.”
A platform presentation, also highlighting underlying disease activity, showed that a new algorithm using conventional MRI can be used as a possible biomarker to automatically detect Slowly Evolving Lesions (SELs), as a potential measure of chronic disease activity outside of acute lesions in the brain. SELs were shown to evolve independently of acute lesions leading to enhanced focal brain tissue loss, as measured by T1 black hole evolution. Further research is needed, but this algorithm for automatic detection of SELs using conventional brain MRI may provide a marker of chronic disease activity in MS lesions.
“This new ability to detect both acute and underlying disease activity with conventional MRI may advance the way we monitor for MS progression and how we think about overall patient management,” said Stephen Hauser, M.D., chair of the Scientific Steering Committee of the OPERA studies, director of the Weill Institute for Neurosciences and chair of the Department of Neurology at the University of California, San Francisco. “While we’ve seen SELs can occur across MS subtypes, this finding may be particularly promising for people with primary progressive MS whose worsening of disability may be related to the presence of SELs. This study also highlights the importance of continued research in MS, not only for development of new treatments such as OCREVUS, but for the insights that are gained about the fundamental cause of this debilitating disease.”
New data from the FLOODLIGHT clinical trial program, which is designed to assess sensor-based outcomes from a series of active neurological tests and passive monitoring through the use of a smartphone is also being presented. The tool enables a continuous stream of precise, real-world MS disease progression data to be collected and analyzed using dedicated algorithms and machine learning.
Data at ECTRIMS – ACTRIMS demonstrate strong patient adherence to the FLOODLIGHT technology. Hand/arm function measured with a smartphone-based pinching test may detect subclinical impairment in those who have normal Nine-Hole Peg Test (9-HPT) performances. Turning speed measured with a smartphone-based U-Turn Test was shown to correlate with the Timed 25-Foot Walk (T25-FW) (p<0.001), and may detect subclinical activity compared to normal in-clinic performances. The data support FLOODLIGHT as a potential complement to in-clinic testing to provide a more complete and consistent picture of a patient’s disease progression.
Additionally, OPERA I, OPERA II and ORATORIO Phase III open-label extension data presented at ECTRIMS – ACTRIMS continue to show a favorable benefit-risk profile for OCREVUS.
OCREVUS has been approved for use in countries across North America, South America, the Middle East, Eastern Europe, as well as in Australia and Switzerland.
Follow Genentech on Twitter via @Genentech and keep up to date with Joint ECTRIMS – ACTRIMS Meeting news and updates by using the hashtag #MSParis2017.
About the OPERA I and OPERA II studies in relapsing forms of MS
OPERA I and OPERA II are Phase III, randomized, double-blind, double-dummy, global multi-center studies evaluating the efficacy and safety of OCREVUS (600 mg administered by intravenous infusion every six months) compared with interferon beta-1a (44 mcg administered by subcutaneous injection three times per week) in 1,656 people with relapsing forms of MS. In these studies, relapsing MS (RMS) was defined as relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) with relapses. A similar proportion of patients in the OCREVUS group experienced serious adverse events and serious infections compared with patients in the high-dose interferon beta-1a group in the RMS studies.
About the ORATORIO study in primary progressive MS

ORATORIO is a Phase III, randomized, double-blind, global multi-center study evaluating the efficacy and safety of OCREVUS (600 mg administered by intravenous infusion every six months; given as two 300 mg infusions two weeks apart) compared with placebo in 732 people with primary progressive MS (PPMS). The blinded treatment period of the ORATORIO study continued until all patients had received at least 120 weeks of either OCREVUS or placebo and a predefined number of confirmed disability progression (CDP) events was reached overall in the study. A similar proportion of patients in the OCREVUS group experienced adverse events and serious adverse events compared with patients in the placebo group in the PPMS study.
Complete Press Release is Found  HERE





MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
...............................................................................

Thursday, October 26, 2017

Biomarkers Aid in Diagnosis, Prognosis of Early Multiple Sclerosis

OCTOBER 11, 2017
Ellen Kurek

No specific biochemical markers have been available to confirm the diagnosis of multiple sclerosis (MS) – until recently.

A Spanish and French research team developed a decision-tree based on results of analysis of biomarkers in the serum and cerebrospinal fluid (CSF) of MS patients. Lidia Fernandez-Paredes, MD (left), and Silvia Sanchez-Ramon, MD (right), both in the department of clinical immunology at Hospital Clinico San Carlos in Madrid, Spain, co-led the research team.  Lidia Fernandez-Paredes, Silvia Sanchez-Ramon, Multiple Sclerosis, MS, Biomarkers

This lack of biomarkers often resulted in a delay in MS diagnosis and treatment while clinicians waited for a relapse to occur or for results of sequential neuroimaging studies to confirm the presence of disseminated lesions in the central nervous system. This study was conducted to provide clinicians with a means of diagnosing MS by using specific biomarkers.

In a previous, cross-sectional study in 2 independent cohorts of MS patients, the team used biologically plausible pathways to identify a panel of 12 biomarkers that might enable investigators to discriminate between the 2 main forms of MS at disease onset — relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). An ability to discriminate between the 2 forms could enable clinicians to make a more specific diagnosis and provide more appropriate treatment sooner, which could delay the disease from becoming irreversibly disabling.

In the current study, the team determined which biomarkers in this panel could be most useful in diagnosing MS in the early phases of the disease as well as in predicting its course. To do this, they collected serum and CSF samples from 89 patients who were recently diagnosed with MS, 97 patients with other neurological diseases (59 non-inflammatory and 38 inflammatory), and 46 age-matched, healthy controls.

After analyzing levels of biomarkers in the samples, the team concluded that serum levels of interleukin-7 (IL-7) and C-X-C motif chemokine ligand 10 (CXCL10) appeared to provide the most accurate means of identifying large differences in disease risk. A serum IL-7 level <141 pg/mL identified patients with MS at onset (odds ratio (OR), 6.5; P < 0.001), and those who also had a CXCL10 level <570 pg/mL were at greatest risk of having the primary progressive form of MS (OR, 22; P = 0.01).

“We started this work years ago in close collaboration with Matthew Albert at the Pasteur Institute in Paris,” Sanchez-Ramon told MD Magazine. “This work is the continuation. Validating these markers at the beginning of clinical manifestations could be especially useful for making therapeutic decisions.”



MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
...............................................................................

Preliminary Results of MS Prevalence Study Estimate Nearly 1 Million Living with MS in the U.S.

NEWS release from The National Multiple Sclerosis Society






October 26, 2017

In a study presented this week at ECTRIMS—the world’s largest MS research meeting—preliminary results from leading experts estimate nearly 1 million people are living with MS in the United States. This is more than twice the previously reported number, which was a result of a 1975 national study and subsequent updates. An important next step in confirming this prevalence number includes anticipated publication in a prominent medical journal.
 
People affected by MS, health care policy experts and researchers have long expressed the need for understanding how many people live with MS in the U.S. A scientifically sound and up to date prevalence estimate will allow us to better understand and address the needs of people with MS and accelerate our impact through advocacy and research. It can help answer such questions as the economic burden of MS on families and society, while ensuring the National MS Society is able to connect to and support all people affected by MS.

READ MORE



MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis

...............................................................................

Pediatric MS Center information updated

Pediactric MS Centers
Doctors and Specialists


For a listing of USA pediatric MS Centers, 
please click here






MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
...............................................................................

Wednesday, October 25, 2017

Excerise.... a Must for both, the MS patient to partake in doing and healthcare providers to promote

10.25.17 -  by:  Jeffrey A. Segal, BS, NSCA-CPT, CSCS, CPTS, CPR/AED
                          Balanced Personal Training, Inc.


Exercise is an essential component of the Multiple Sclerosis patient’s treatment plan. Unfortunately, until the 1990’s, exercise was highly regarded as contraindicated to MS patients. In 1993, the first medicine was approved by the FDA for MS and in 1996; the first research showing the benefits of exercise was published by the University of Utah. These were two major breakthroughs which have given hope to a population consisting of the most common disabling neurological disease of young adults (most common onset between ages 20 and 50).


Multiple Sclerosis is a neuroinflammatory autoimmune disease of the central nervous system (CNS), consisting of the brain, spinal cord and optic nerve.  The immune system attacks the myelin sheath of the nerves which insulates, protects as well as affects the signal speed from the CNS to the affected body part. Presentation of initial symptom of MS include optic nerve inflammation, poor balance (ataxia), dizziness (vertigo), weakness, double vision (diplopia), bladder/bowel dysfunction, pain, sensory loss, cognitive impairment, fatigue (most common) and a host of others including but not limited to gait impairment, depression,  tremors, thermo-regulatory dysfunction (autonomic) and spasticity. Because many symptoms are invisible (not outwardly visible), most notably fatigue, pain and cognitive impairment, they can affect confidence, relationships, and discourage patients from seeking treatment or help.

Currently, with more than 16 FDA approved disease modifying treatments, as well as exercise being greatly encouraged by health care providers treating MS, the face of MS is changing for the better. While exercise will not change the course of the disease progression, both aerobic and anaerobic conditioning have greatly helped reduce secondary and tertiary symptoms such as falls, injuries, anxiety/depression, impaired activities of daily living (secondary) and increase self-esteem, and  independence while reducing social isolation and family disruption (tertiary).

The benefits of a safe, progressive/adaptive exercise program are improved overall fitness, ability to perform activities of daily living, moods, sense of well-being, strength while decreasing spasticity, fatigue and may prevent a host of co-morbidities. Because MS patients may be less mobile and underweight/overweight, coupled with the possibility of side effects from the use of corticosteroids, it increases the likelihood of developing conditions such as osteoporosis and diabetes mellitus. This is an even a greater reason those affected with MS should work with professionals who understand the disease.




Although many patients are still hesitant to begin an exercise program because of fear of exacerbating their condition, lack of confidence or inability to find professionals skilled to work with them, now is the best time in the history of MS treatment for both patients and professionals to be on the same page. Exercise no longer has to be an activity of an MS patient’s past. It is simply a must of the present and future.     

............................................................................................................................

Monday, October 23, 2017

Multiple Sclerosis Risk Significantly Associated With Vitamin D Deficiency

Vitamin D deficiency is significantly associated with risk for multiple sclerosis.
Vitamin D deficiency represents a significant risk factor for multiple  sclerosis (MS), necessitating the need for greater public outreach and interventions to improve vitamin D levels in the population, according to a case-control study published in Neurology.

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
...............................................................................

Managing Urinary Retention in Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, resulting in a variety of nonspecific neurologic symptoms.Bladder problems are one of the many primary symptoms of the disease and are highly prevalent among MS patients.1,2 According to results of the 2005 North American Research Committee on Multiple Sclerosis survey, 65% of MS patients have experienced at least one urinary symptom described as moderate to severe in severity.2 Additionally, analysis of the survey found that approximately 25% of MS patients perform intermittent catheterization, which significantly impacts their quality of life.
When discussing the pathophysiology of urinary retention in MS patients, it is important to consider the role of the bladder detrusor.2 The detrusor muscle is comprised of three overlapping layers of smooth muscle as well as a surrounding extracellular matrix that acts as a support. Sympathetic nervous system stimulation of alpha- and beta- adrenergic receptors relax the detrusor muscle, allowing for bladder filling and storage. Conversely, parasympathetic stimulation of muscarinic cholinergic receptors contract the muscle, causing emptying of the bladder. In patients with MS, urinary retention can be due to an underactive detrusor muscle and/or an obstruction of the bladder outlet due to detrusor sphincter dyssynergia (DSD). Both imaging and data obtained from previous studies indicate that these causes actually occur due to disruptions in neurologic signaling rather than from primary detrusor failure.
Continue Reading




MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
...............................................................................

Sunday, October 22, 2017

Study Reveals CBD 'May' Help These 12 Conditions

The revealing truth about CBD

CBD oil

CBD has come into the spot light throughout 2017 being acknowledged for its anti-inflammatory properties and its ability to help several intractable diseases. It has become so popular that it is now being used and researched for several conditions such as irritable bowel diseases and pain relief.

What is CBD?

CBD (Cannabidiol) is one of the natural cannabinoids found in the Cannabis Sativa plant. Unlike THC, which is known to produce a psychoactive effect, CBD does not cause a high and has, therefore, become classed as a medical compound that can treat a variety of diseases.
According to a recent study in the British Journal of Clinical Pharmacology, it was found that CBD possess unique healing properties;
  • Antiemetic – Reduces nausea and vomiting
  • Anticonvulsant – Suppresses seizure activity
  • Antipsychotic – Combats psychosis disorders
  • Anti-inflammatory – Combats inflammatory disorders
  • Anti-oxidant – Combats neurodegenerative disorders
  • Anti-tumoral/Anti-cancer – Combats tumor and cancer cells
  • Anxiolytic/Anti-depressant – Combats anxiety and depression disorders

The Legal Status on CBD Oil

CBD oil located in stores or at least the ones you see on shelves are normally manufactured from Hemp, but if you live in a medical or recreational state, you will find CBD Oil made from the cannabis plant.
What’s the difference?
Hemp plants are grown in different conditions to marijuana plants. Hemp plants are often stalky and tall, grown aptly in fields similar to corn.
Marijuana plants are stubbier and much shorter. Marijuana is normally produced under conditions that allow for THC to be highly present among its plant constituents.
The major difference between the two is that Hemp has hardly any THC but instead other phytocannabinoids, terpenes, and CBD.
From a legal aspect, the marijuana plant is currently classed as a schedule 1 drug and therefore on a Federal level it is illegal. Individual states have introduced laws legalizing the plant and have turned into medical or recreational states. This means that if you reside in a medical state that permits the use of cannabis for specific treatments you will most likely be allowed to use CBD Oil.
But what happens if you live in a restricted state?
Obviously, CBD Marijuana Oil that will get you high is out of the questions, but CBD Hemp Oil is a completely different story. According to projectCBD.org, “Federal law prohibits U.S. farmers from cultivating hemp as a commercial crop, but the sale of imported, low-THC, industrial hemp products is permitted in the United States. This is as long as these products are derived from the seed or stalk of the plant, not from the leaves and flowers.”
Sounds amazing, right? Well, it depends on who you ask. If you read the Agricultural Farm Bill of 2014, you won’t find a clear answer on that topic. Nevertheless, what we do understand, is that companies like PureKana and GreenRoads are paving the way to alternative medical health, helping people from all 50 states by shipping their CBD Oil to patient’s doorsteps.
Whether it’s legal, or borderline, it seems to be working for millions of people over the U.S. Here are the top conditions that CBD Hemp Oil seems to be helping with.

Ailments that CBD Oil seems to help With

  1. Cancer and cancer treatments
  2. Epilepsy and other neurological disorders
  3. Anxiety and depression
  4. Insomnia and sleep disorders
  5. Pain and inflammation
  6. Diabetes and diabetic nerve pain
  7. Cardiovascular disease
  8. Arthritis
  9. Spasms
  10. Multiple Sclerosis
  11. PTSD
  12. Stress relief

Final Thoughts About CBD and Where to Start  -- click here to continue reading



MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
...............................................................................

Additional often needed resources for those with Disability

MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
...............................................................................